RU94031161A - PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING, METHOD FOR TREATING DISORDERS DEVELOPING DUE TO NEURODEGENERATIVE PROCESSES - Google Patents

PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING, METHOD FOR TREATING DISORDERS DEVELOPING DUE TO NEURODEGENERATIVE PROCESSES

Info

Publication number
RU94031161A
RU94031161A RU94031161/14A RU94031161A RU94031161A RU 94031161 A RU94031161 A RU 94031161A RU 94031161/14 A RU94031161/14 A RU 94031161/14A RU 94031161 A RU94031161 A RU 94031161A RU 94031161 A RU94031161 A RU 94031161A
Authority
RU
Russia
Prior art keywords
obtaining
pharmaceutical composition
treating disorders
neurodegenerative processes
developing due
Prior art date
Application number
RU94031161/14A
Other languages
Russian (ru)
Other versions
RU2125448C1 (en
Inventor
Мадьяр Кальман
Гаал Йожеф
Сираки Иштван
Лендьел Йожеф
Сабо Анна
Мармароши Каталин
Хермец Иштван
Сатмари Иштван
Терек Золтан
Кермеци Петер
Original Assignee
Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU914060A external-priority patent/HUT63579A/en
Application filed by Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ filed Critical Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ
Publication of RU94031161A publication Critical patent/RU94031161A/en
Application granted granted Critical
Publication of RU2125448C1 publication Critical patent/RU2125448C1/en

Links

Claims (1)

Изобретение относится к двухфазным фармацевтическим композициям, содержащим ингибитор МАО и ингибитор поглощения в качестве активного ингредиента в сочетании со стандартными фармацевтическими добавками. Указанные композиции могут быть использованы для лечений нейродегенеративных заболеваний. В этих композициях, в качестве активного ингредиента, т.е. ингибитора МАО и ингибитора поглощения, могут быть использованы N-(1-фенилизопропил)-N-метилпропиламин или N-(4-фторфенил)-изопроп-1-ил-Н-метилпропиламин, или их соли, оптически активные изомеры или метаболиты.The invention relates to a two-phase pharmaceutical compositions containing an MAO inhibitor and an absorption inhibitor as an active ingredient in combination with standard pharmaceutical additives. These compositions can be used to treat neurodegenerative diseases. In these compositions, as an active ingredient, i.e. MAO inhibitor and absorption inhibitor, N- (1-phenylisopropyl) -N-methylpropylamine or N- (4-fluorophenyl) -isoprop-1-yl-N-methylpropylamine, or their salts, optically active isomers or metabolites can be used.
RU94031161A 1991-12-20 1992-12-18 Pharmaceutical composition and a method of its preparing, method of treatment of disorders caused by neurodegenerative processes RU2125448C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU4060/91 1991-12-20
HU914060A HUT63579A (en) 1991-12-20 1991-12-20 Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
PCT/HU1992/000060 WO1993012775A1 (en) 1991-12-20 1992-12-18 Pharmaceutical composition and process for the preparation thereof

Publications (2)

Publication Number Publication Date
RU94031161A true RU94031161A (en) 1996-03-27
RU2125448C1 RU2125448C1 (en) 1999-01-27

Family

ID=10966728

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94031161A RU2125448C1 (en) 1991-12-20 1992-12-18 Pharmaceutical composition and a method of its preparing, method of treatment of disorders caused by neurodegenerative processes

Country Status (27)

Country Link
US (1) US5589513A (en)
EP (1) EP0617615A1 (en)
JP (1) JPH07502730A (en)
KR (1) KR940703655A (en)
AU (1) AU677170B2 (en)
BG (1) BG98827A (en)
BR (1) BR9206950A (en)
CA (1) CA2125776A1 (en)
CZ (1) CZ147494A3 (en)
EC (1) ECSP930933A (en)
EE (1) EE03015B1 (en)
FI (1) FI942932A (en)
HU (2) HUT63579A (en)
IL (1) IL104150A (en)
LT (1) LT3119B (en)
LV (1) LV10386B (en)
MY (1) MY111055A (en)
NO (1) NO942303D0 (en)
NZ (1) NZ246384A (en)
PH (1) PH31073A (en)
PL (1) PL172048B1 (en)
RO (1) RO115785B1 (en)
RU (1) RU2125448C1 (en)
SI (1) SI9200404A (en)
SK (1) SK74494A3 (en)
WO (1) WO1993012775A1 (en)
ZA (1) ZA929883B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
DE4432610C1 (en) * 1994-09-13 1996-02-01 Knoll Ag Process for the preparation of selegiline hydrochloride
JPH10513455A (en) 1995-02-10 1998-12-22 ザ ユニバーシティ オブ トロント イノベーションズ ファウンデーション Deprenyl compounds for the treatment of glaucoma
JP4499208B2 (en) 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション Novel optically active aminopentane derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HUP9902482A2 (en) * 1999-07-22 2002-04-29 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Use of p-fluoro-selegiline for producing neuroprotective pharmaceutical compositions
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DE102009045056A1 (en) * 2009-09-28 2011-03-31 Henkel Ag & Co. Kgaa Spotting preparations
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (en) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Process for the preparation of phenylisopropylamines
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
DE3764144D1 (en) * 1986-04-16 1990-09-13 Asta Pharma Ag SYNERGISTIC COMBINATION OF AMANTADINE AND SELEGILINE.
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
GB9011767D0 (en) * 1990-05-25 1990-07-18 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals

Similar Documents

Publication Publication Date Title
RU94031161A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING, METHOD FOR TREATING DISORDERS DEVELOPING DUE TO NEURODEGENERATIVE PROCESSES
NO961687D0 (en) New (R) -5-carbamoyl-8-fluoro-3-N, N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
DK0495776T3 (en) Stabilizing nitric oxide / primary amine complexes useful as cardiovascular agents
DE3484573D1 (en) PENETRIC TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING N- (2-HYDROXYETHYL) -PYRROLIDONE.
DE60126980D1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES
MX9100990A (en) MOMETASONE FUROATE MONOHYDRATE COMPOUND, THE PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS
BR9406979A (en) Compound, pharmaceutical composition for treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent processes for treating an inflammatory disease and for preparing a pharmaceutically acceptable salt compound use of a non-steroidal anti-inflammatory pharmaceutical composition compound
DE122009000012I1 (en) Substituted pyrazolylbenzenesulfonamides for the treatment of inflammation.
DE69716810D1 (en) 2,3-disubstituted-(5,6) -heteroarylkondensierte-pyrimidin-4-one
BR9507073A (en) Composed processes to prepare the same and to treat a disease in the central nervous system pharmaceutical composition and use of the compound
ES2136252T3 (en) TREATMENT OF DISEASES CAUSED BY SEBACEA GLAND DISORDERS THROUGH THE USE OF ACIL COA CHOLESTEROL ACIL TRANSFERASE INHIBITORS.
BG98827A (en) Pharmaceutical composition and method for its preparation
MX24839A (en) 3-ARYCARBONYL-1-AMINOALKYL-1H-INDOLES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION WHICH IT CONTAINS.
NO983530L (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
DK1032556T3 (en) Pharmaceutically active compounds and methods of use
RU93053905A (en) OXYPURINE NUCLEOSIDES AND RELATED COMPOUNDS THEREOF, AND ALSO THEIR Acyl DERIVATIVES TO IMPROVE HEMOPOESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT AND / OR PREVENTION
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
DK0634396T3 (en) Amino acid derivatives and their use as single phalinase inhibitors
DE69808475D1 (en) AMINO ACID DERIVATIVES FOR TREATING STROKE
ATE48759T1 (en) TREATMENT OF ATTACKS AND USEFUL PHARMACEUTICAL COMPOSITIONS THEREOF.
NO970573L (en) Yliden compounds and their preparation
DE3380923D1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS CONDITIONED BY HUMAN DRUGS.
ATE110714T1 (en) HYDROXAMIC ACID DERIVATIVES WHICH INHIBIT LIPOXYGENASE.
ES2054790T3 (en) COMPOUNDS THAT HAVE CARDIOVASCULAR ACTIVITY.
SE8402199D0 (en) PHARMACEUTICAL PREPARATION CONTAINING CO-DERGOCRINE AND ONE CALCIUM ANTAGONISTS